In 147 adults with primary biliary cholangitis and moderate-to-severe itch, linerixibat (20–180 mg daily) cut worst daily itch by ≥2 points at week 16 but not significantly more than placebo; post hoc analyses suggested dose-related benefit. Diarrhoea rose with dose.
Secondary analysisn = 147
Levy et al. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus